Diabetes Drug Of India’s Dr. Reddy’s Hits Danish Trial Firm Problems
This article was originally published in PharmAsia News
Executive Summary
A Danish company conducting a Phase III trial on a diabetes drug for India's Dr. Reddy's Laboratories has encountered financial problems, possibly delaying the drug's introduction. Rheoscience has the Indian drug maker's balaglitizone in trials as a treatment for Type 2 diabetes and the drug was considered ahead of Indian competitors with launching possible as early as 2011. If Rheoscience cannot finish the trials, its parent, Nordic Bioscience is considered likely to finish them. (Click here for more
You may also be interested in...
SkyePharma Stops Feasibility Study On Drug Delivery Systems With Dr Reddy’s
Mumbai - London-based specialized drug delivery technology company SkyePharma announced as part of its management statement Oct. 27 that the collaborative feasibility project with Dr Reddy's Labs has been stopped pending further assessment
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.